Most Down Articles

Published in last 1 year | In last 2 years| In last 3 years| All| Most Downloaded in Recent Month | Most Downloaded in Recent Year|

Most Downloaded in Recent Year

Please wait a minute...


For Selected: Download Citations EndNote Reference Manager ProCite BibTeX RefWorks Toggle Thumbnails

Select

Electronic Journal of Liver Tumor    2024, 11 (3): 1-13.   Abstract （68）      PDF （1944KB）（406）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Research progress on occupational stress formation of oncology nurses A-yun ZHAO, Jing-hui Li, Na Zhuang, Yun Liu Electronic Journal of Liver Tumor    2019, 6 (4): 36-38.   Abstract （168）   HTML （6）    PDF （1187KB）（501）       Knowledge map    Save At present, the incidence of cancer is increasing year by year, and oncology nurses also need to face more and more work pressure. Compared with nurses in general departments, oncology nurses should not only carry out necessary nursing for cancer patients, but also comprehensively master the medication, observation, nursing and psychological counseling for cancer patients. High-intensity work and persistent physical and mental burden not only affect the mental health status of nurses, but also reduce the quality of care. Therefore, from the perspective of occupational stress of nurses in hospital oncology department, this paper makes an in-depth analysis of the factors that affect the pressure of nurses in the daily nursing process, and puts forward corresponding improvement strategies, attaching importance to the professional management of nurses, effectively relieving the pressure of nurses, and promoting the sustainable and healthy development of their mental health and nursing quality. Reference | Related Articles | Metrics

Select

Nomogram model of prognosis of hepatocellular carcinoma patients was constructed based on NRS-2002 Wang Chao, Han Shanshan, Chen Shu, Ding Shengyi, Feng Zhiqiang Electronic Journal of Liver Tumor    2020, 7 (3): 22-29.   Abstract （56）      PDF （2558KB）（176）       Knowledge map    Save Objective: The nutritional risk Assessment Form (NRS-2002) was used to assess the nutritional status of patients with hepatocellular carcinoma (HCC) and to construct a Nomogram model to predict the recurrence of HCC patients in combination with other risk factors. Methods: The clinical data of 241 patients with HCC underwent hepatectomy in Suixi County People's Hospital, Beijing Chaoyang Emergency Rescue Center and Air Force Characteristic Medical Center from July 2015 to January 2019 were retrospectively analyzed. Univariate and multivariate Cox proportional risk models were used to analyze the independent risk factors for recurrence and death of HCC patients. Nomogram model was constructed according to independent risk factors.Internal data were used to verify the effectiveness of the Nomogram model. Results: ROC curve was used to analyze the correlation variables according to the mortality of HCC patients.The AUC of age, AFP, TBIL, ALT and ALB were 0.783, 0.715, 0.758, 0.729 and 0.822, respectively.The optimal truncation values were 65years、400μg/L、34.67μmol/L、40.54U/L、35g/L, respectively.The proportion of cirrhosis(yes), TBIL (>34.67μmol/L) and ALB(≤35g/L)in patients with malnutrition was higher than that in patients with normal nutrition (P<0.05).At the end of follow-up, 127 of the 241 HCC patients relapsed, with a median relapse-free survival of 14 months and 101 deaths of 19 months.The relapse-free survival rate and overall survival rate of nutritionally normal patients were higher than that of malnutrition patients (P<0.05).Multiariable Cox risk proportion model analysis results showed that liver cirrhosis (YES), tumor diameter (>5cm), TNM staging(Ⅲ+Ⅳ), TBIL (>34.67 μmol) and NRS-2002 (malnutrition) are independent risk factors for recurrence of HCC patients (P<0.05);Cirrhosis of the liver (YES), tumor diameter (>5cm), TNM staging(Ⅲ+Ⅳ)are the independent risk factors of death in patients with HCC (P<0.05).The results of internal validation showed that the 6 month, 12 month and 24 month recurrence free survival rates were 0.716(95%CI: 0.671-0.866), 0.710(95%CI: 0.624-0.838) and 0.699 (95%CI: 0.611-0.796), respectively. Conclusion: In this study, the Nomogram model was effective in predicting the recurrence free survival rate of HCC patients at 6, 12, and 24 months after surgery, which could be used to improve the perioperative treatment plan . Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2021, 8 (3): 69-72.   Abstract （110）      PDF （2782KB）（234）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Local therapy for unresectable intrahepatic cholangiocarcinoma Li Shupei, Yu Chenxi, Lai Fengyong, Song Peng, Du Chunxia, Yao xuesong Electronic Journal of Liver Tumor    2020, 7 (4): 44-47.   Abstract （116）      PDF （1561KB）（226）       Knowledge map    Save Intrahepatic cholangiocarcinoma refers to a malignant tumor that originates from the epithelial cells of the secondary bile duct and the branches of the intrahepatic bile duct. With the characteristics of difficult early diagnosis, high malignancy and poor prognosis. Although intrahepatic cholangiocarcinoma is relatively rare, it’s still the second most common primary malignant tumor of the liver following the hepatocellular carcinoma. In recent years, the morbidity and mortality of intrahepatic cholangiocarcinoma have been increasing. Surgical resection is currently the only radical cure, but most patients have lost the opportunity for surgery when they are diagnosed. With local treatment technology has made great progress. Those patients with unresectable intrahepatic cholangiocarcinoma, could get benefits from local treatment in terms of tumor burden reducing, symptoms relieved, prolong survival, and even transforming to surgery available. The current common local treatment methods mainly include: ablation treatment, transvascular treatment and radiotherapy. This article reviews the current status and progress of the main local treatments for intrahepatic cholangiocarcinoma. In order to get more approaches to multiple discipline therapy in intrahepatic cholangiocarcinoma. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (3): 43-45.   Abstract （73）      PDF （1519KB）（203）       Knowledge map    Save Related Articles | Metrics

Select

Analysis of incidence and mortality of liver cancer in Shanxi cancer registries, 2019 Guo Xuerong, Cao Ling, Zhang Ruifeng, Wang Xinchen, Qiao Nan, Zhang Yongzhen Electronic Journal of Liver Tumor    2023, 10 (2): 27-32.   Abstract （149）      PDF （2308KB）（181）       Knowledge map    Save Objective: To analyze the incidence and mortality of liver cancer in Shanxi cancer registries in 2019, and to provide the strategies of prevention and treatment of liver cancer. Method: According to the "Chinese Guideline for Cancer Registration" and referring to the data quality audit evaluation standards formulated by the International Agency for Research on Cancer (IARC)/International Association of Cancer Registration (IACR), a summary analysis was conducted on the incidence, death, and population data of liver cancer reported by tumor registration points in Shanxi Province that meet the quality control standards. The incidence/mortality crude rate, standardized incidence/mortality rate, and the cumulative rate of 0-74 years old were calculated by gender, area (urban and rural), and age. The age-standardized of Chinese standard population (ASR China) and world standard population (ASR world) were calculated by the Chinese standard population in 2000 and Segi's population, respectively. Result: In 2019, 644 new cases of liver cancer were recorded in Shanxi cancer registries, accounting for 5.39% of all new cancer cases. The crude incidence rate was 13.18 per 100 000, with ASR China of 8.13 per 100 000 and ASR world of 8.30 per 100 000, respectively. The cumulative incidence rate (0-74 years old) was 0.96%. Liver cancer was the 7th most common cancer in the registration areas of China in 2019. The incidence of ASR China was 2.46 times in males as that in females, and it was 0.99 times in urban areas as that in rural areas. A total of 791 cases died of liver cancer in Shanxi cancer registries, accounting for 10.00% of all cancer deaths. The crude mortality rate was 16.19 per 100 000, with ASR China of 9.90 per 100 000 and ASR world of 10.06 per 100 000. The cumulative mortality rate (0-74 years old) was 1.16%. Liver cancer was the 4th most common cause of cancer deaths in the registration areas of China in 2019. The mortality of ASR China was 1.90 times in males as that in females, and it was 0.78 times in urban areas as that in rural areas. The incidence and mortality of liver cancer both increased with age, and the incidence increased more significantly after the age of 40. The incidence and mortality in Shanxi Province reached the peak in the age group of 85 years, and the male was higher than the female. Conclusion: The incidence and mortality rates of liver cancer in Shanxi cancer registries are lower than national average, the male is higher than the female, and higher in rural areas than in urban areas. Therefore, the prevention and treatment of liver cancer should focus on males and pelple in rural areas. Early diagnosis and treatment of liver cancer should be promoted to increase the detection rate of early liver cancer and reduce the disease burden caused by liver cancer. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (3): 48-51.   Abstract （60）      PDF （2088KB）（210）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (1): 51-53.   Abstract （128）      PDF （1598KB）（171）       Knowledge map    Save Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2019, 6 (4): 39-42.   Abstract （160）   HTML （6）    PDF （2274KB）（303）       Knowledge map    Save Table and Figures | Reference | Related Articles | Metrics

Select

Effect of phased psychological intervention on the treatment of pain and anxiety after TACE in patients with primary liver cancer Li Ying, Cheng Fei, Ren Wei, He Ruixian Electronic Journal of Liver Tumor    2020, 7 (4): 48-51.   Abstract （77）      PDF （1532KB）（126）       Knowledge map    Save Objective: To investigate the effect of phased psychological intervention onthe treatment of pain and anxiety after TACE in patients with primary liver cancer(PLC). Methods:A total of 200 patients with primary liver cancer who were treated with transcatheter arterial chemoembolization were randomly divided into two groups, with 100 patients in each group. Control group was given conventional care while the study group was intervention group based on conventional care Implement phased psychological intervention. The number rating scales (NRS) pain score and the degree of anxiety were compared between the two groups. Results:The NRS scores of both groups showed a downward trend after operation. The pain scores of the intervention group at 24、48 and 72 hours after surgery were lower than those of the control group (P<0.05), and the patient anxiety scores were lower than those of the control group (P<0.05). Conclusion: Phased psychological intervention can effectively reduce the pain and anxiety of patients with primary liver cancer after TACE. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (2): 2-11.   Abstract （233）      PDF （1680KB）（422）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Exploration on diagnosis and treatment of hepatobiliary malignancies by big data Lu Shanshan, Jia Xiaodong, Zhang Ning, Zeng Zhen, Lu Yinying Electronic Journal of Liver Tumor    2020, 7 (2): 52-55.   Abstract （98）      PDF （1760KB）（156）       Knowledge map    Save Hepatobiliary malignancies are common in digestive system diseases, which are occult and develop rapidly, especially in advanced hepatobiliary malignancies, it's low radical cure rate and high mortality are still one of the most difficult problems in clinical practice. In recent years, with the rise of big data and the advancement of accurate diagnosis and treatment plan, a number of new clinical decisions and treatment strategies have emerged. In the field of hepatobiliary malignancies, the perfect combination of big data and precision medicine will help many medical scholars to understand the biological characteristics of hepatobiliary malignancies more deeply and comprehensively, and then reveal the driving genes and pathogenesis of hepatobiliary malignancies; The integration and analysis of big data will also promote the implementation of individualized and precision medicine, and improve the standardized diagnosis and treatment level of hepatobiliary malignancies. In addition, it can also bring new light and hope for breaking through the bottleneck of treatment of advanced hepatobiliary malignancies. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (4): 54-58.   Abstract （255）      PDF （2920KB）（307）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Research progress in immunotherapy and biomarkers for hepatocellular carcinoma Peng Xuenan, Zhou Aiping Electronic Journal of Liver Tumor    2020, 7 (4): 17-22.   Abstract （91）      PDF （1654KB）（412）       Knowledge map    Save The incidence of hepatocellular carcinoma (HCC) in China ranked fourth among all malignant tumors, and the mortality rate ranked second in 2015. Approximately 85% of Chinese patients are in the intermediate stage or advanced stage at the first visit and lose the best treatment chance. The 5-year survival rate of them is only 12%. Since 2007, treatments for advanced hepatocellular carcinoma mostly focused on targeted therapy, with limited efficacy. In recent years, immune checkpoint inhibitors have achieved 17% ~ 20% and 15% ~ 20% objective response rate in first-line and second-line monotherapy respectively. Immunotherapy shows obviously anti-tumor effect that is superior to traditional targeted therapy. Initial results have also achieved in the field of neoadjuvant and adjuvant therapy for HCC. However, several challenges such as treatment selection after disease progression and disease recurrence after liver transplantation are still unsolved. Exploring immune-specific biomarkers to predict the efficacy has also become an important direction in the field of immunotherapy. In this review, we summarized the research progress of immunotherapy and biomarkers for hepatocellular carcinoma. Reference | Related Articles | Metrics

Select

Global liver cancer and gallbladder cancer incidence and mortality in 2020 Shan Tianhao1, An Lan1, Xu Mengyuan1, Zeng Hongmei1,*, Cai Jianqiang2,* Electronic Journal of Liver Tumor    2022, 9 (4): 46-51.   Abstract （358）      PDF （2337KB）（262）       Knowledge map    Save Objective:According to the data of GLOBOCAN 2020, we compared the global and Chinese incidence and mortality of liver cancer and gallbladder cancer in 2020, to provide a scientific basis for cancer prevention and control. Method:According to the incidence and mortality data of liver cancer and gallbladder cancer released by the International Agency for Research on Cancer in 2020, the differences among different regions, genders and ages were compared. Result:In 2020, there were 905 677 new cases and 830 180 deaths of liver cancer globally, with age-standardized incidence and mortality rates of 9.5/100 000 and 8.7/100 000, respectively. For gallbladder cancer, the numbers of new cases and deaths were 115 949 and 84 695, respectively, with the age-standardized incidence and mortality of 1.2/100 000 and 0.84/100 000, respectively. The top five countries with highest incidence of liver cancer were Mongolia, Egypt, Laos, Cambodia and Vietnam. The top five countries with highest incidence of gallbladder cancer were Bolivia, Chile, Bangladesh, Nepal and Korea. In 2020, there were 410 038 new cases of liver cancer in China, with a standardized incidence rate of 18.2/100 000, ranking 8th among all countries. There were 391 152 new cases of death from liver cancer in China, with an age-standardized mortality rate of 17.2/100 000. For gallbladder cancer, there were 28 923 new cases of incidence in China, with an age-standardized incidence rate of 1.2/100 000, ranking 39th among all countries. There were 23 297 new cases of death from gallbladder cancer in China, with an age-standardized mortality rate of 0.97/100 000. Conclusion:The disease burden of liver cancer and gallbladder cancer is different between countries. Different prevention and control strategies should be formulated according to different populations. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (1): 65-69.   Abstract （65）      PDF （2314KB）（214）       Knowledge map    Save Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (3): 47-47.   Abstract （57）      PDF （1344KB）（65）       Knowledge map    Save Related Articles | Metrics

Select

The prognostic value of simple inflammation-related indexes in predicting liver transplantation for hepatocellular carcinoma Cao Yin, Wang Zhongxia, Jiang Chunping Electronic Journal of Liver Tumor    2021, 8 (3): 35-40.   Abstract （60）      PDF （1547KB）（261）       Knowledge map    Save Liver transplantation is an important treatment for hepatocellular carcinoma, but the recurrence rate remains unsatisfied. Systemic inflammatory response can be reflected by a number of common serological markers including neutrophils, lymphocytes, platelets, C-reactive protein and simple inflammatory indexes constructed by these factors. Many researches reported that these inflammatory indexes are important to predict the prognosis of HCC patients underwent liver transplantation. The purpose of this review is to summarize the published work on the prognostic value of simple inflammation based markers such as neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio, systemic immune inflammation index, prognostic nutrient index, and Glasgow prognostic score in HCC patients following liver transplantation. Reference | Related Articles | Metrics

Select

Radiotherapy compared with palliative care for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification Yang Liu, Zhu Xiling, Jin Shuai, Chang Na, Zhao Yufei, Li Gong Electronic Journal of Liver Tumor    2020, 7 (3): 7-11.   Abstract （105）      PDF （1645KB）（134）       Knowledge map    Save Objective: To evaluate the efficiency of radiotherapy (RT) for unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) and the significance of Cheng's classification for the prognosis. Methods: A retrospective analysis was performed on 105 patients with HCC with PVTT in the Third Medical Center of PLA General Hospital from January 2010 to October 2016, among whom 67 underwent RT and 38 received palliative care. Survival analysis of the two treatment groups was performed with Kaplan-Meier and then stratified by Cheng’s classification of PVTT. And the prognostic factors were analyzed. Results: The median survival,1-year, 2-year and 5-year survival rate of RT group and palliative group was 9 vs. 3 months, 41.8% vs. 2.6%, 20.1% vs. 0, 4.5% vs. 0. On subgroup analysis of PVTT, the median survival in the RT group for type Ⅱ, Ⅲ, and Ⅳ PVTT was 13, 8, and 5 months, respectively. In RT group, the survival of type III was better than type IV (P = 0.044), but inferior to type II (P = 0.011). PVTT type, tumor number and RT dose were independent prognostic factors for survival (P = 0.041, P = 0.028, P = 0.015). Conclusions: Radiotherapy is an effective treatment compared with palliative care for HCC and PVTT, and Cheng's classification can initially provide a better prognosis evaluation for HCC with PVTT who underwent radiotherapy. Reference | Related Articles | Metrics